An early post-transplant relapse prediction ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT.
Author(s) :
Beksac, Meral [Auteur]
Ankara University School of Medicine [Turkey]
Iacobelli, Simona [Auteur]
Koster, Linda [Auteur]
Leiden University Medical Center [LUMC]
Cornelissen, Jan [Auteur]
Erasmus University Medical Center [Rotterdam] [Erasmus MC]
Griskevicius, Laimonas [Auteur]
Vilnius University [Vilnius]
Rabin, Neil K. [Auteur]
University College of London [London] [UCL]
Stoppa, Anne Marie [Auteur]
Institut Paoli-Calmettes [IPC]
Meijer, Ellen [Auteur]
VU University Medical Center [Amsterdam]
Mear, Jean-Baptiste [Auteur]
Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou]
Zeerleder, Sacha [Auteur]
Universität Bern = University of Bern = Université de Berne [UNIBE]
Mayer, Jiri [Auteur]
University Hospital Brno
Fenk, Roland [Auteur]
Heinrich Heine Universität Düsseldorf = Heinrich Heine University [Düsseldorf]
Fegueux, Nathalie [Auteur]
Hôpital Lapeyronie [CHU Montpellier]
Chevallier, Patrice [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Konirova, Eva [Auteur]
Univerzita Karlova [Praha, Česká republika] = Charles University [Prague, Czech Republic] [UK]
Snowden, John A. [Auteur]
Sheffield Children's NHS Foundation Trust
Engelhardt, Monika [Auteur]
Universitäts Klinikum Freiburg = University Medical Center Freiburg [Uniklinik]
Orchard, Kim [Auteur]
University Hospital Southampton NHS Foundation Trust
Hulin, Cyrille [Auteur]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Schaap, Nicolaas [Auteur]
Radboud University Medical Center [Nijmegen]
Sossa, Claudia [Auteur]
Universidad Autónoma de Bucaramanga [UNAB]
Elmaagacli, Ahmet [Auteur]
Asklepios Klinikum Harburg [Hamburg, Germany] [AKH]
Mclornan, Donal P. [Auteur]
Queen's University [Belfast] [QUB]
Hayden, Patrick J. [Auteur]
Trinity College Dublin
Schönland, Stefan [Auteur]
University of Heidelberg, Medical Faculty
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Ankara University School of Medicine [Turkey]
Iacobelli, Simona [Auteur]
Koster, Linda [Auteur]
Leiden University Medical Center [LUMC]
Cornelissen, Jan [Auteur]
Erasmus University Medical Center [Rotterdam] [Erasmus MC]
Griskevicius, Laimonas [Auteur]
Vilnius University [Vilnius]
Rabin, Neil K. [Auteur]
University College of London [London] [UCL]
Stoppa, Anne Marie [Auteur]
Institut Paoli-Calmettes [IPC]
Meijer, Ellen [Auteur]
VU University Medical Center [Amsterdam]
Mear, Jean-Baptiste [Auteur]
Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou]
Zeerleder, Sacha [Auteur]
Universität Bern = University of Bern = Université de Berne [UNIBE]
Mayer, Jiri [Auteur]
University Hospital Brno
Fenk, Roland [Auteur]
Heinrich Heine Universität Düsseldorf = Heinrich Heine University [Düsseldorf]
Fegueux, Nathalie [Auteur]
Hôpital Lapeyronie [CHU Montpellier]
Chevallier, Patrice [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Konirova, Eva [Auteur]
Univerzita Karlova [Praha, Česká republika] = Charles University [Prague, Czech Republic] [UK]
Snowden, John A. [Auteur]
Sheffield Children's NHS Foundation Trust
Engelhardt, Monika [Auteur]
Universitäts Klinikum Freiburg = University Medical Center Freiburg [Uniklinik]
Orchard, Kim [Auteur]
University Hospital Southampton NHS Foundation Trust
Hulin, Cyrille [Auteur]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Schaap, Nicolaas [Auteur]
Radboud University Medical Center [Nijmegen]
Sossa, Claudia [Auteur]
Universidad Autónoma de Bucaramanga [UNAB]
Elmaagacli, Ahmet [Auteur]
Asklepios Klinikum Harburg [Hamburg, Germany] [AKH]
Mclornan, Donal P. [Auteur]
Queen's University [Belfast] [QUB]
Hayden, Patrick J. [Auteur]
Trinity College Dublin
Schönland, Stefan [Auteur]
University of Heidelberg, Medical Faculty
Yakoub-Agha, Ibrahim [Auteur]

Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Journal title :
Bone Marrow Transplantation
Abbreviated title :
Bone Marrow Transplant
Publication date :
2023-05-11
ISSN :
1476-5365
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Early relapse (ER) following Autologous Hematopoietic Cell Transplantation (AHCT) confers a poor prognosis. We therefore developed a novel scoring system to predict ER. A total of 14,367 AHCT-1 patients were transplanted ...
Show more >Early relapse (ER) following Autologous Hematopoietic Cell Transplantation (AHCT) confers a poor prognosis. We therefore developed a novel scoring system to predict ER. A total of 14,367 AHCT-1 patients were transplanted between 2014 and 2019, and were conditioned with Melphalan 200 mg/m2 (Mel200) (n = 7228; 2014–2017) (training cohort); Mel200 (n = 5616; 2018–2019) or Mel140 (n = 1523; 2018–2019) (validation cohorts). PFS-12 and the Cumulative Incidence of Relapse at 12 months were 84.1% and 14.7% (training Mel200), 87.2% and 11.6% (validation Mel200), and 80.3% and 16.9% (validation Mel140), respectively. The points in the risk score were: 0, 1,2 for ISS stages I, II, and III; Disease status: 0 (CR/VGPR); 1 (PR); 2 (SD/MR); 4 (Relapse/Progression); and 1 for Karnofsky ≤ 70. The distribution of scores: 0 (24%), 1 (33.9%), 2 (29.6 %), 3 (9.5%), and ≥4 (2.7%). The score separated PFS-12, with the lowest risk group (n = 1752) having a PFS-12 of 91.7% and the highest risk group (n = 195) 57.1%. This also applied in cytogenetically high-risk patients. If the pre-score baseline risks are 15% (standard risk) and 25% (high-risk), a score of ≥4 confers calculated risks of 38% and 54%, respectively. This novel EBMT ER score, therefore, allows for the identification of five discrete prognostic groups.Show less >
Show more >Early relapse (ER) following Autologous Hematopoietic Cell Transplantation (AHCT) confers a poor prognosis. We therefore developed a novel scoring system to predict ER. A total of 14,367 AHCT-1 patients were transplanted between 2014 and 2019, and were conditioned with Melphalan 200 mg/m2 (Mel200) (n = 7228; 2014–2017) (training cohort); Mel200 (n = 5616; 2018–2019) or Mel140 (n = 1523; 2018–2019) (validation cohorts). PFS-12 and the Cumulative Incidence of Relapse at 12 months were 84.1% and 14.7% (training Mel200), 87.2% and 11.6% (validation Mel200), and 80.3% and 16.9% (validation Mel140), respectively. The points in the risk score were: 0, 1,2 for ISS stages I, II, and III; Disease status: 0 (CR/VGPR); 1 (PR); 2 (SD/MR); 4 (Relapse/Progression); and 1 for Karnofsky ≤ 70. The distribution of scores: 0 (24%), 1 (33.9%), 2 (29.6 %), 3 (9.5%), and ≥4 (2.7%). The score separated PFS-12, with the lowest risk group (n = 1752) having a PFS-12 of 91.7% and the highest risk group (n = 195) 57.1%. This also applied in cytogenetically high-risk patients. If the pre-score baseline risks are 15% (standard risk) and 25% (high-risk), a score of ≥4 confers calculated risks of 38% and 54%, respectively. This novel EBMT ER score, therefore, allows for the identification of five discrete prognostic groups.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
Université de Lille
Inserm
CHU Lille
Inserm
CHU Lille
Submission date :
2024-01-11T22:46:04Z
2024-03-25T14:46:43Z
2024-03-25T14:46:43Z